Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal cancer (CRC) and to define the dose limiting toxicities associated with the combination.
Anal, Colon, and Rectal Cancers|Colorectal Neoplasms|Colon/Rectal Cancer
DRUG: Vandetanib|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Bevacizumab
Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab, Following treatment
Effect of vandetanib on the pharmacokinetics (PK) of capecitabine and oxaliplatin, During and following treatment|Effects of this treatment on tumor remission, progression free survival, and overall survival of patients, Following treatment|Dose limiting toxicities associated with the combination, During and following treatment
To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal cancer (CRC) and to define the dose limiting toxicities associated with the combination.